CRISPR Therapeutics AG

CRISPR Therapeutics AG financial statements

CRISPR Therapeutics AG's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

FY2025

RevenueUSD 3.51M10-K
Net income−USD 581.6M10-K
Cash and equivalentsUSD 347.56M10-Q
Total debtUSD 010-Q

CRISPR Therapeutics AG financials on 6ix · CRISPR Therapeutics AG on 6ix